Neptune's Final Receipt for Resale Prospectus
September 23 2011 - 8:00PM
Neptune Technologies & Bioressources Inc. ("Neptune" or the
"Corporation") (Nasdaq:NEPT) (TSX-V:NTB) announces the grant on
September 23, 2011 of the final receipt by the securities
regulatory authority in the Province of Québec in connection with
the resale prospectus of Neptune.
This short form base shelf prospectus (the
"Prospectus") allows the periodic resale from time
to time by the Selling Securityholders identified under the heading
"Selling Securityholders" on page 6 of the Prospectus available on
SEDAR at www.sedar.com of some or all of 2,722,222 of our common
shares and 680,556 warrants (the "US
warrants"), currently held by the Selling
Securityholders (the "offering"). Each whole
warrant entitles the holder thereof to purchase one of Neptune
common shares at a price of US$ 2.75 per share at any time on or
before 4:00 p.m. (EDT) on October 27, 2012. In this Prospectus, we
refer to the foregoing collectively as the "Registrable
Securities."
This Prospectus was filed with the securities regulatory
authority in the Province of Québec (the "Qualifying
Jurisdiction"), in order to qualify the resale of the
Registrable Securities in the United States.
The registration of the securities covered by this Prospectus
does not necessarily mean that any of the securities will be
offered or sold by the Selling Securityholders.
This Prospectus is part of a "shelf" registration statement
filed with the Securities and Exchange Commission (the
"SEC"). This Prospectus may be used by the Selling
Securityholders in connection with resale of the Registrable
Securities in the United States from time to time during the period
that this Prospectus, including any amendments thereto, remains
valid.
The Registrable Securities may be offered by the Selling
Securityholders in negotiated transactions or otherwise, to or
through underwriters or dealers purchasing as principal or directly
to purchasers at varying prices determined at the time of the sale
or at negotiated prices. In addition, the Registrable Securities
may be offered from time to time through ordinary brokerage
transactions on the TSXV or NASDAQ.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Corporation focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Corporation
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma (TSX-V:APO) is developing a product portfolio of
proprietary novel long-chain omega-3 phospholipids. Phospholipids
are the major component of cell membranes and are essential for all
vital cell processes. They are one of the principal constituents of
High Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by astaxanthin, a potent antioxidant. Acasti Pharma is focusing
initially on treatments for chronic cardiovascular and
cardiometabolic conditions within the over-the-counter, medical
food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release."
Statements in this press release that
are not statements of historical or current fact constitute
"forward-looking statements" within the meaning of the U.S.
Private Securities Litigation Reform Act of 1995 and Canadian
securities laws. Such forward-looking statements involve known and
unknown risks, uncertainties, and other unknown factors that could
cause the actual results of the Company to be materially different
from historical results or from any future results expressed or
implied by such forward-looking statements. In addition to
statements which explicitly describe such risks and
uncertainties, readers are urged to consider statements
labeled with the terms "believes," "belief," "expects," "intends,"
"anticipates," "will," or "plans" to be uncertain and
forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that
are described from time to time in the Company's reports filed with
the Securities and Exchange Commission and the Canadian securities
commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
CEOcast Contact:
Dan Schustack
+1 212-732-4300
dschustack@ceocast.com
www.ceocast.com
Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024